204 related articles for article (PubMed ID: 19797073)
1. Long-term immunity to lethal acute or chronic type II Toxoplasma gondii infection is effectively induced in genetically susceptible C57BL/6 mice by immunization with an attenuated type I vaccine strain.
Gigley JP; Fox BA; Bzik DJ
Infect Immun; 2009 Dec; 77(12):5380-8. PubMed ID: 19797073
[TBL] [Abstract][Full Text] [Related]
2. Nonreplicating, cyst-defective type II Toxoplasma gondii vaccine strains stimulate protective immunity against acute and chronic infection.
Fox BA; Bzik DJ
Infect Immun; 2015 May; 83(5):2148-55. PubMed ID: 25776745
[TBL] [Abstract][Full Text] [Related]
3. Cell-mediated immunity to Toxoplasma gondii develops primarily by local Th1 host immune responses in the absence of parasite replication.
Gigley JP; Fox BA; Bzik DJ
J Immunol; 2009 Jan; 182(2):1069-78. PubMed ID: 19124750
[TBL] [Abstract][Full Text] [Related]
4. DNA immunization with eukaryotic initiation factor-2α of Toxoplasma gondii induces protective immunity against acute and chronic toxoplasmosis in mice.
Chen J; Huang SY; Zhou DH; Li ZY; Petersen E; Song HQ; Zhu XQ
Vaccine; 2013 Dec; 31(52):6225-31. PubMed ID: 24183979
[TBL] [Abstract][Full Text] [Related]
5. A Lactate Fermentation Mutant of
Xia N; Zhou T; Liang X; Ye S; Zhao P; Yang J; Zhou Y; Zhao J; Shen B
Front Immunol; 2018; 9():1814. PubMed ID: 30147689
[No Abstract] [Full Text] [Related]
6. Vaccination with Toxoplasma gondii calcium-dependent protein kinase 6 and rhoptry protein 18 encapsulated in poly(lactide-co-glycolide) microspheres induces long-term protective immunity in mice.
Zhang NZ; Xu Y; Wang M; Chen J; Huang SY; Gao Q; Zhu XQ
BMC Infect Dis; 2016 Apr; 16():168. PubMed ID: 27090890
[TBL] [Abstract][Full Text] [Related]
7. Homologous prime-boost strategy with TgPI-1 improves the immune response and protects highly susceptible mice against chronic Toxoplasma gondii infection.
Sánchez VR; Fenoy IM; Picchio MS; Soto AS; Arcon N; Goldman A; Martin V
Acta Trop; 2015 Oct; 150():159-65. PubMed ID: 26200784
[TBL] [Abstract][Full Text] [Related]
8.
Wang JL; Liang QL; Li TT; He JJ; Bai MJ; Cao XZ; Elsheikha HM; Zhu XQ
J Immunol; 2020 Mar; 204(6):1562-1570. PubMed ID: 31996457
[TBL] [Abstract][Full Text] [Related]
9. Humoral responses and immune protection in mice immunized with irradiated T. gondii tachyzoites and challenged with three genetically distinct strains of T. gondii.
Zorgi NE; Costa A; Galisteo AJ; do Nascimento N; de Andrade HF
Immunol Lett; 2011 Aug; 138(2):187-96. PubMed ID: 21545808
[TBL] [Abstract][Full Text] [Related]
10. IL-15 prolongs the duration of CD8+ T cell-mediated immunity in mice infected with a vaccine strain of Toxoplasma gondii.
Khan IA; Casciotti L
J Immunol; 1999 Oct; 163(8):4503-9. PubMed ID: 10510393
[TBL] [Abstract][Full Text] [Related]
11. Mast cell activator compound 48/40 is not an effective adjuvant for UV-attenuated Toxoplasma gondii vaccine.
Li X; Chen S; Huang S; Lu F
Parasitol Res; 2017 Aug; 116(8):2347-2353. PubMed ID: 28573462
[TBL] [Abstract][Full Text] [Related]
12. Partially protective vaccination permits the development of latency in a normally virulent strain of Toxoplasma gondii.
Yap GS; Scharton-Kersten T; Ferguson DJ; Howe D; Suzuki Y; Sher A
Infect Immun; 1998 Sep; 66(9):4382-8. PubMed ID: 9712791
[TBL] [Abstract][Full Text] [Related]
13. A live attenuated RHΔompdcΔuprt mutant of Toxoplasma gondii induces strong protective immunity against toxoplasmosis in mice and cats.
Shen Y; Zheng B; Sun H; Wu S; Fan J; Ding J; Gao M; Kong Q; Lou D; Ding H; Zhuo X; Lu S
Infect Dis Poverty; 2023 Jun; 12(1):60. PubMed ID: 37322556
[TBL] [Abstract][Full Text] [Related]
14. C57BL/6 mice immunized with synthetic peptides from Toxoplasma gondii surface and microneme immunodominant antigens are able to decrease parasite burden in the brain tissues.
Barros HLS; Santana SS; Pajuaba ACAM; da Silva Cardoso Barros P; Dos Reis de Carvalho F; de Paiva VF; Wilson Patriarca Mineo T; Mineo JR
Acta Trop; 2019 Aug; 196():1-6. PubMed ID: 31059707
[TBL] [Abstract][Full Text] [Related]
15. DNA vaccine encoding the Toxoplasma gondii bradyzoite-specific surface antigens SAG2CDX protect BALB/c mice against type II parasite infection.
Zhang M; Zhao L; Song J; Li Y; Zhao Q; He S; Cong H
Vaccine; 2013 Sep; 31(41):4536-40. PubMed ID: 23933373
[TBL] [Abstract][Full Text] [Related]
16. A GRA1 DNA vaccine primes cytolytic CD8(+) T cells to control acute Toxoplasma gondii infection.
Scorza T; D'Souza S; Laloup M; Dewit J; De Braekeleer J; Verschueren H; Vercammen M; Huygen K; Jongert E
Infect Immun; 2003 Jan; 71(1):309-16. PubMed ID: 12496180
[TBL] [Abstract][Full Text] [Related]
17. Plant Hsp90 is a novel adjuvant that elicits a strong humoral and cellular immune response against B- and T-cell epitopes of a Toxoplasma gondii SAG1 peptide.
Sánchez-López EF; Corigliano MG; Albarracín RM; Sander VA; Legarralde A; Bengoa-Luoni SA; Clemente M
Parasit Vectors; 2019 Mar; 12(1):140. PubMed ID: 30909938
[TBL] [Abstract][Full Text] [Related]
18. Animal Models for Toxoplasma gondii Infection.
S Subauste C; Hubal A
Curr Protoc; 2023 Sep; 3(9):e871. PubMed ID: 37695167
[TBL] [Abstract][Full Text] [Related]
19. Immunity in the spleen and blood of mice immunized with irradiated Toxoplasma gondii tachyzoites.
Zorgi NE; Galisteo AJ; Sato MN; do Nascimento N; de Andrade HF
Med Microbiol Immunol; 2016 Aug; 205(4):297-314. PubMed ID: 26732075
[TBL] [Abstract][Full Text] [Related]
20. Inducible nitric oxide synthase is not required for long-term vaccine-based immunity against Toxoplasma gondii.
Khan IA; Matsuura T; Kasper LH
J Immunol; 1998 Sep; 161(6):2994-3000. PubMed ID: 9743363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
